Efficacy Prediction of T cell Subsets in Kidney-Supplementing Medicinal Combined with Anti-Lymphocyte Globulin/Anti-Thymocyte Globulin for Severe Aplastic Anemia

TANG Xudong; ZHANG Shanshan; XU Yonggang; YANG Xiaohong; LI Liu; LIU Feng; MA Rou

doi:10.13288/j.11-2166/r.2013.20.026

您当前的位置：

首页 >

文章列表页 >

Efficacy Prediction of T cell Subsets in Kidney-Supplementing Medicinal Combined with Anti-Lymphocyte Globulin/Anti-Thymocyte Globulin for Severe Aplastic Anemia

更新时间：2021-11-17

- Efficacy Prediction of T cell Subsets in Kidney-Supplementing Medicinal Combined with Anti-Lymphocyte Globulin/Anti-Thymocyte Globulin for Severe Aplastic Anemia
- Journal of Traditional Chinese Medicine Vol. 54, Issue 20, Pages: 1755-1758(2013)
- 作者机构：
  
  中国中医科学院西苑医院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2013.20.026
  CLC： R556
- Published：2013
- 稿件说明：
移动端阅览
[1]唐旭东,张姗姗,许勇钢,杨晓红,李柳,刘锋,麻柔.T细胞亚群在重型再生障碍性贫血治疗中的疗效预测价值[J].中医杂志,2013,54(20):1755-1758.

TANG Xudong, ZHANG Shanshan, XU Yonggang, et al. Efficacy Prediction of T cell Subsets in Kidney-Supplementing Medicinal Combined with Anti-Lymphocyte Globulin/Anti-Thymocyte Globulin for Severe Aplastic Anemia[J]. Journal of Traditional Chinese Medicine2013, 54(20): 1755-1758.
[1]唐旭东,张姗姗,许勇钢,杨晓红,李柳,刘锋,麻柔.T细胞亚群在重型再生障碍性贫血治疗中的疗效预测价值[J].中医杂志,2013,54(20):1755-1758. DOI： 10.13288/j.11-2166/r.2013.20.026.

TANG Xudong, ZHANG Shanshan, XU Yonggang, et al. Efficacy Prediction of T cell Subsets in Kidney-Supplementing Medicinal Combined with Anti-Lymphocyte Globulin/Anti-Thymocyte Globulin for Severe Aplastic Anemia[J]. Journal of Traditional Chinese Medicine2013, 54(20): 1755-1758. DOI： 10.13288/j.11-2166/r.2013.20.026.

摘要

目的探讨CD3+HLA-DR+T和CD3+CD25+T细胞亚群在以补肾中药联合抗淋巴细胞球蛋白/抗胸腺细胞球蛋白（ALG/ATG）为主治疗重型再生障碍性贫血（简称重型再障）中的疗效预测价值。方法采用补肾中药联合ALG/ATG对71例重型再障患者进行治疗

辅以环孢菌素A、雄激素、造血生长因子等

检查重型再障患者治疗前后CD3+HLA-DR+T和CD3+CD25+T细胞亚群的免疫学指标变化。结果重型再障经补肾中药联合ATG/ALG治疗后

有效患者（59例）的CD3+CD25+T较无效患者（12例）明显升高（P<0.05）

CD3+HLA-DR+T、CD3+HLA-DR+T/CD3+CD25+T与重型再障的疗效无明显相关性（P>0.05）。经过Kaplan-Meier过程

CD3+HLA-DR+T细胞比例>7%时

CD3+CD25+T细胞比例>3%时

CD3+HLA-DR+T/CD3+CD25+T细胞≤2.5时患者生存期较长（P<0.05）。结论 CD3+CD25+T可作为重型再障疗效预测性指标

其升高提示疗效较佳;CD3+HLA-DR+T细胞比例>7%、CD3+CD25+T细胞比例>3%、CD3+HLA-DR+T/CD3+CD25+T细胞≤2.5提示预后较好

生存期较长。

Abstract

Objective To study the efficacy prediction of CD3+HLA-DR+T and CD3+CD25+T cell subsets in kidneysupplementing medicinal combined with anti-lymphocyte globulin/anti-thymocyte globulin（ALG/ATG）for severe aplastic anemia（SAA）.Methods Totally 71cases of SAA were given the combo therapy of kidney-supplementing medicinal

ALG/ ATG

Cyclosporin A

androgens and hematopoietic growth factors.The percentages of CD3+HLA-DR+T and CD3+CD25+T were detected before and after treatment.Results The percentage of CD3+CD25+T was significantly increased in the effective cases after treatment（P<0.05）.There was no significant difference between the therapeutic effect and the percentage of CD3+HLA-DR+T and CD3+HLA-DR+T/CD3+CD25+T（P>0.05）.The survival was prolonged when the percentage of CD3+HLA-DR+T exceeded 7%（P<0.05）

the percentage of CD3+CD25+T exceeded 3%（P<0.05）and CD3+HLA-DR+ T/CD3+CD25+T was less than or equal to 2.5（P<0.05）after Kaplan-Meier procedure.Conclusion The percentage of CD3+CD25+T can be taken as the indicator of efficacy prediction and its exaltation suggests a better efficacy.The survival is prolonged when the percentage of CD3+HLA-DR+T exceeds 7%

the percentage of CD3+CD25+T exceeds 3% and CD3+ HLA-DR+T/CD3+CD25+T is less than or equal to 2.5.

关键词

Keywords

references

查看原文

Views

301

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

基于“肾欲坚，急食苦以坚之，用苦补之”探讨绝经后骨质疏松症的防治

Clinical Studies on Actions of Replenishing Kidney andEssence on Brain Function in the Elderly

Clinical Observation on 30 Cases of Asthenic - yang Type Aplastic Anemia Treated Mainly with Bushen Compound

Effects of Drugs for Strengthening -Spleen Tonifying - Kidney on Cellular Immunity in Hemodialysis for Chronic Renal Failure

Effect of Bushen （Kidney - tonification） Huayu （Stasis - elimination） on Indices of Marrow Cyto enzymology in Aplastic Anemia

Related Author

刘渊

申重阳

李嘉炜

李春财

原明星

谢竹藩

王学美

吴翰香

Related Institution

成都中医药大学，四川省成都市温江区柳台大道1166号

北京医科大学中西医结合研究所

北京医科大学中西医结合研究所北京西城区西安门大街1号

上海中医药大学曙光医院

上海中医药大学曙光医院上海市普安路185号

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰